{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:52:31Z","timestamp":1793868751322,"version":"4.6.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hemab Therapeutics ApS","id":[{"id":"https:\/\/ror.org\/05dqjxj38","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cardiovasc Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Inherited bleeding disorders such as Glanzmann thrombasthenia (GT) lack prophylactic treatment options. As a result, serious bleeding episodes are treated acutely with blood product transfusions or frequent, repeated intravenous administration of recombinant activated coagulation factor VII (rFVIIa). Here we describe HMB-001, a bispecific antibody designed to bind and accumulate endogenous FVIIa and deliver it to sites of vascular injury by targeting it to the TREM (triggering receptor expressed on myeloid cells)-like transcript-1 (TLT-1) receptor that is selectively expressed on activated platelets. In healthy nonhuman primates, HMB-001 prolonged the half-life of endogenous FVIIa, resulting in its accumulation. Mouse bleeding studies confirmed antibody-mediated potentiation of FVIIa hemostatic activity by TLT-1 targeting. In ex vivo models of GT, HMB-001 localized FVIIa on activated platelets and potentiated fibrin-dependent platelet aggregation. Taken together, these results indicate that HMB-001 has the potential to offer subcutaneous prophylactic treatment to prevent bleeds in people with GT and other inherited bleeding disorders, with a low-frequency dosing regimen.<\/jats:p>","DOI":"10.1038\/s44161-023-00418-4","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T06:02:50Z","timestamp":1707372170000},"page":"166-185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7949-4899","authenticated-orcid":false,"given":"Prafull S.","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4545-7939","authenticated-orcid":false,"given":"Minka","family":"Zivkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalie C.","family":"Bonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Elm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika N.","family":"L\u00f8vgreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Schluckebier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9330-5169","authenticated-orcid":false,"given":"Eva","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-7521","authenticated-orcid":false,"given":"Ole H.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva H. N.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1061-8352","authenticated-orcid":false,"given":"Ian-Arris","family":"de Bus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karien","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Alsk\u00e4r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren E.","family":"Bj\u00f8rn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2762-6033","authenticated-orcid":false,"given":"Roger E.","family":"Schutgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1601-9393","authenticated-orcid":false,"given":"Rolf T.","family":"Urbanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan H.","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"418_CR1","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1055\/s-0042-1756188","volume":"48","author":"M Franchini","year":"2022","unstructured":"Franchini, M. & Mannucci, P. M. The more recent history of hemophilia treatment. Semin. Thromb. Hemost. 48, 904\u2013910 (2022).","journal-title":"Semin. Thromb. Hemost."},{"key":"418_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ajh.26018","volume":"96","author":"SE Croteau","year":"2021","unstructured":"Croteau, S. E., Wang, M. & Wheeler, A. P. 2021 clinical trials update: innovations in hemophilia therapy. Am. J. Hematol. 96, 128\u2013144 (2021).","journal-title":"Am. J. Hematol."},{"key":"418_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","volume":"21","author":"PM Mannucci","year":"2023","unstructured":"Mannucci, P. M. Hemophilia treatment innovation: 50 years of progress and more to come. J. Thromb. Haemost. 21, 403\u2013412 (2023).","journal-title":"J. Thromb. Haemost."},{"key":"418_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1046\/j.1365-2141.2003.04286.x","volume":"121","author":"AM Almeida","year":"2003","unstructured":"Almeida, A. M., Khair, K., Hann, I. & Liesner, R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br. J. Haematol. 121, 477\u2013481 (2003).","journal-title":"Br. J. Haematol."},{"key":"418_CR5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood-2019-130298","volume":"134","author":"MB Chitlur","year":"2019","unstructured":"Chitlur, M. B. et al. An update on rFVIIa use in females with rare bleeding disorders. Blood 134, 1119 (2019).","journal-title":"Blood"},{"key":"418_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1182\/asheducation-2016.1.663","volume":"2016","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi, F. & Menegatti, M. Treatment of rare factor deficiencies in 2016. Hematology Am. Soc. Hematol. Educ. Program 2016, 663\u2013669 (2016).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"418_CR7","first-page":"113","volume":"88","author":"WE Glanzmann","year":"1918","unstructured":"Glanzmann, W. E. Hereditary haemorrhagic thrombasthenia. A contribution to the pathology of platelets. Yearb. Pediatr. 88, 113\u2013141 (1918).","journal-title":"Yearb. Pediatr."},{"key":"418_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/JBM.S271744","volume":"12","author":"N Mathews","year":"2021","unstructured":"Mathews, N., Rivard, G.-E. & Bonnefoy, A. Glanzmann thrombasthenia: perspectives from clinical practice on accurate diagnosis and optimal treatment strategies. J. Blood Med. 12, 449\u2013463 (2021).","journal-title":"J. Blood Med."},{"key":"418_CR9","unstructured":"Krause, K. A. & Graham, B. C. Glanzmann thrombasthenia. in StatPearls www.ncbi.nlm.nih.gov\/books\/NBK538270\/ (StatPearls Publishing, 2023)."},{"key":"418_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14713","author":"K Khair","year":"2023","unstructured":"Khair, K. SP011 Glanzmann\u2019s 360 study. Speaker abstracts. Haemophilia https:\/\/doi.org\/10.1111\/hae.14713 (2023).","journal-title":"Haemophilia"},{"key":"418_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/ajh.20159","volume":"77","author":"G Toogeh","year":"2004","unstructured":"Toogeh, G. et al. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am. J. Hematol. 77, 198\u2013199 (2004).","journal-title":"Am. J. Hematol."},{"key":"418_CR12","first-page":"1031","volume":"100","author":"G Di Minno","year":"2015","unstructured":"Di Minno, G. et al. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica 100, 1031\u20131037 (2015).","journal-title":"Haematologica"},{"key":"418_CR13","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2003-07-2287","volume":"103","author":"T Lisman","year":"2004","unstructured":"Lisman, T., Adelmeijer, J., Heijnen, H. F. & de Groot, P. G. Recombinant factor VIIa restores aggregation of \u03b1IIb\u03b23-deficient platelets via tissue factor-independent fibrin generation. Blood 103, 1720\u20131727 (2004).","journal-title":"Blood"},{"key":"418_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1365-2141.2006.06343.x","volume":"135","author":"PHB Bolton-Maggs","year":"2006","unstructured":"Bolton-Maggs, P. H. B. et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br. J. Haematol. 135, 603\u2013633 (2006).","journal-title":"Br. J. Haematol."},{"key":"418_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/joah.joah_68_18","volume":"10","author":"A Tarawah","year":"2019","unstructured":"Tarawah, A. et al. Management of Glanzmann thrombasthenia\u2014guidelines based on an expert panel consensus from Gulf Cooperation Council countries. J. Appl. Hematol. 10, 1\u20139 (2019).","journal-title":"J. Appl. Hematol."},{"key":"418_CR16","unstructured":"Novo Nordisk. NovoSeven, R.T. Coagulation factor VIIa (recombinant). Summary of product characteristics. www.novo-pi.com\/novosevenrt.pdf (2020)."},{"key":"418_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.tmrv.2016.01.001","volume":"30","author":"M-C Poon","year":"2016","unstructured":"Poon, M.-C., Di Minno, G., d\u2019Oiron, R. & Zotz, R. New insights into the treatment of Glanzmann thrombasthenia. Transfus. Med. Rev. 30, 92\u201399 (2016).","journal-title":"Transfus. Med. Rev."},{"key":"418_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/MBC.0000000000001026","volume":"32","author":"N Andi\u00e7","year":"2021","unstructured":"Andi\u00e7, N., O\u011fuz, N., G\u00fcnd\u00fcz, E., Kiraz Bulduk, T. & \u00dcsk\u00fcdar Teke, H. Weekly low-dose recombinant factor VIIa prophylaxis in Glanzmann thrombasthenia. Blood Coagul. Fibrinolysis 32, 349\u2013351 (2021).","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"418_CR19","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1182\/blood-2013-08-522987","volume":"123","author":"D Feng","year":"2014","unstructured":"Feng, D., Whinna, H., Monroe, D. & Stafford, D. W. FVIIa as used pharmacologically is not TF dependent in hemophilia B mice. Blood 123, 1764\u20131766 (2014).","journal-title":"Blood"},{"key":"418_CR20","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1046\/j.1538-7836.2003.00225.x","volume":"1","author":"T Lisman","year":"2003","unstructured":"Lisman, T. & De Groot, P. G. Mechanism of action of recombinant factor VIIa. J. Thromb. Haemost. 1, 1138\u20131139 (2003).","journal-title":"J. Thromb. Haemost."},{"key":"418_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/2040620717737701","volume":"8","author":"M Giansily-Blaizot","year":"2017","unstructured":"Giansily-Blaizot, M. & Schved, J. F. Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date. Ther. Adv. Hematol. 8, 345\u2013352 (2017).","journal-title":"Ther. Adv. Hematol."},{"key":"418_CR22","first-page":"S15","volume":"9","author":"DM Monroe","year":"1998","unstructured":"Monroe, D. M., Hoffman, M., Oliver, J. A. & Roberts, H. R. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul. Fibrinolysis 9, S15\u2013S20 (1998).","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"418_CR23","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1182\/blood.V95.4.1330.004k28_1330_1335","volume":"95","author":"C van \u2018t Veer","year":"2000","unstructured":"van \u2018t Veer, C., Golden, N. J. & Mann, K. G. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood 95, 1330\u20131335 (2000).","journal-title":"Blood"},{"key":"418_CR24","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1182\/blood-2014-05-576892","volume":"124","author":"C Augustsson","year":"2014","unstructured":"Augustsson, C. & Persson, E. In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia. Blood 124, 3172\u20133174 (2014).","journal-title":"Blood"},{"key":"418_CR25","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1182\/blood-2002-09-2761","volume":"101","author":"T Lisman","year":"2003","unstructured":"Lisman, T., Moschatsis, S., Adelmeijer, J., Nieuwenhuis, H. K. & De Groot, P. G. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired \u03b1IIb\u03b23 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 101, 1864\u20131870 (2003).","journal-title":"Blood"},{"key":"418_CR26","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1111\/j.1538-7836.2011.04293.x","volume":"9","author":"A Tiede","year":"2011","unstructured":"Tiede, A. et al. Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa). J. Thromb. Haemost. 9, 1191\u20131199 (2011).","journal-title":"J. Thromb. Haemost."},{"key":"418_CR27","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.1538-7836.2007.02389.x","volume":"5","author":"M Kjalke","year":"2007","unstructured":"Kjalke, M., Kjellev, S. & Rojkjaer, R. Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist. J. Thromb. Haemost. 5, 774\u2013780 (2007).","journal-title":"J. Thromb. Haemost."},{"key":"418_CR28","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/hae.13312","volume":"23","author":"I Fern\u00e1ndez-Bello","year":"2017","unstructured":"Fern\u00e1ndez-Bello, I. et al. The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B. Haemophilia 23, 868\u2013876 (2017).","journal-title":"Haemophilia"},{"key":"418_CR29","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1182\/blood.V118.21.2252.2252","volume":"118","author":"D Pittman","year":"2011","unstructured":"Pittman, D. et al. A novel FVIIa variant with increased potency and duration of effect compared to wildtype FVIIa. A study in a dog model of hemophilia A. Blood 118, 2252 (2011).","journal-title":"Blood"},{"key":"418_CR30","doi-asserted-by":"publisher","first-page":"13583","DOI":"10.1073\/pnas.241339498","volume":"98","author":"E Persson","year":"2001","unstructured":"Persson, E., Kjalke, M. & Olsen, O. H. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc. Natl Acad. Sci. USA 98, 13583\u201313588 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"418_CR31","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/j.1538-7836.2012.04667.x","volume":"10","author":"JN Mahlangu","year":"2012","unstructured":"Mahlangu, J. N. et al. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J. Thromb. Haemost. 10, 773\u2013780 (2012).","journal-title":"J. Thromb. Haemost."},{"key":"418_CR32","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1160\/TH08-04-0268","volume":"100","author":"HR Stennicke","year":"2008","unstructured":"Stennicke, H. R. et al. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Thromb. Haemost. 100, 920\u2013928 (2008).","journal-title":"Thromb. Haemost."},{"key":"418_CR33","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1160\/TH07-08-0525","volume":"99","author":"T Weimer","year":"2008","unstructured":"Weimer, T. et al. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb. Haemost. 99, 659\u2013667 (2008).","journal-title":"Thromb. Haemost."},{"key":"418_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/hae.13428","volume":"24","author":"A Bar-Ilan","year":"2018","unstructured":"Bar-Ilan, A. et al. In vitro characterization of MOD-5014, a novel long-acting carboxy-terminal peptide (CTP)-modified activated FVII. Haemophilia 24, 477\u2013486 (2018).","journal-title":"Haemophilia"},{"key":"418_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1055\/s-0032-1302442","volume":"38","author":"E Persson","year":"2012","unstructured":"Persson, E., Olsen, O. H., Bjorn, S. E. & Ezban, M. Vatreptacog alfa from conception to clinical proof of concept. Semin. Thromb. Hemost. 38, 274\u2013281 (2012).","journal-title":"Semin. Thromb. Hemost."},{"key":"418_CR36","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood.V126.23.2269.2269","volume":"126","author":"MM Aleman","year":"2015","unstructured":"Aleman, M. M. et al. Platelet-targeted rFVIIa\u2013Xten improves thrombin generation and fibrin formation compared to recombinant FVIIa. Blood 126, 2269 (2015).","journal-title":"Blood"},{"key":"418_CR37","doi-asserted-by":"publisher","first-page":"13396","DOI":"10.1074\/jbc.M600489200","volume":"281","author":"JL Gattis","year":"2006","unstructured":"Gattis, J. L. et al. The structure of the extracellular domain of triggering receptor expressed on myeloid cells like transcript-1 and evidence for a naturally occurring soluble fragment. J. Biol. Chem. 281, 13396\u201313403 (2006).","journal-title":"J. Biol. Chem."},{"key":"418_CR38","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1182\/blood-2004-01-0315","volume":"104","author":"AV Washington","year":"2004","unstructured":"Washington, A. V. et al. A TREM family member, TLT-1, is found exclusively in the \u03b1-granules of megakaryocytes and platelets. Blood 104, 1042\u20131047 (2004).","journal-title":"Blood"},{"key":"418_CR39","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1182\/bloodadvances.2018017756","volume":"2","author":"CW Smith","year":"2018","unstructured":"Smith, C. W. et al. TREM-like transcript 1: a more sensitive marker of platelet activation than P-selectin in humans and mice. Blood Adv. 2, 2072\u20132078 (2018).","journal-title":"Blood Adv."},{"key":"418_CR40","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1172\/JCI36175","volume":"119","author":"AV Washington","year":"2009","unstructured":"Washington, A. V. et al. TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans. J. Clin. Invest. 119, 1489\u20131501 (2009).","journal-title":"J. Clin. Invest."},{"key":"418_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jth.14644","volume":"18","author":"M Enoksson","year":"2020","unstructured":"Enoksson, M. et al. Enhanced potency of recombinant factor VIIa with increased affinity to activated platelets. J. Thromb. Haemost. 18, 104\u2013113 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"418_CR42","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1073\/pnas.1220145110","volume":"110","author":"AF Labrijn","year":"2013","unstructured":"Labrijn, A. F. et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc. Natl Acad. Sci. USA 110, 5145\u20135150 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"418_CR43","doi-asserted-by":"publisher","first-page":"14477","DOI":"10.1016\/S0021-9258(19)49737-8","volume":"267","author":"PF Neuenschwander","year":"1992","unstructured":"Neuenschwander, P. F. & Morrissey, J. H. Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function. Analysis of a mutant with a selective deficiency in activity. J. Biol. Chem. 267, 14477\u201314482 (1992).","journal-title":"J. Biol. Chem."},{"key":"418_CR44","doi-asserted-by":"publisher","first-page":"21489","DOI":"10.1016\/S0021-9258(20)80565-1","volume":"268","author":"PF Neuenschwander","year":"1993","unstructured":"Neuenschwander, P. F., Fiore, M. M. & Morrissey, J. H. Factor VII autoactivation proceeds via interaction of distinct protease\u2013cofactor and zymogen\u2013cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism. J. Biol. Chem. 268, 21489\u201321492 (1993).","journal-title":"J. Biol. Chem."},{"key":"418_CR45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1538-7836.2010.04152.x","volume":"9","author":"H Agers\u00f8","year":"2011","unstructured":"Agers\u00f8, H. et al. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients. J. Thromb. Haemost. 9, 333\u2013338 (2011).","journal-title":"J. Thromb. Haemost."},{"key":"418_CR46","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/338518a0","volume":"338","author":"TJ Girard","year":"1989","unstructured":"Girard, T. J. et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338, 518\u2013520 (1989).","journal-title":"Nature"},{"key":"418_CR47","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/09537104.2021.1881948","volume":"32","author":"S Branfield","year":"2021","unstructured":"Branfield, S. & Washington, A. V. The enigmatic nature of the triggering receptor expressed in myeloid cells-1 (TLT-1). Platelets 32, 753\u2013760 (2021).","journal-title":"Platelets"},{"key":"418_CR48","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1182\/blood-2018-03-841593","volume":"132","author":"J Morales-Ortiz","year":"2018","unstructured":"Morales-Ortiz, J. et al. Platelet-derived TLT-1 is a prognostic indicator in ALI\/ARDS and prevents tissue damage in the lungs in a mouse model. Blood 132, 2495\u20132505 (2018).","journal-title":"Blood"},{"key":"418_CR49","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1182\/blood-2012-04-416594","volume":"120","author":"JM Burkhart","year":"2012","unstructured":"Burkhart, J. M. et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 120, e73\u2013e82 (2012).","journal-title":"Blood"},{"key":"418_CR50","doi-asserted-by":"publisher","first-page":"28168","DOI":"10.1074\/jbc.271.45.28168","volume":"271","author":"CD McCallum","year":"1996","unstructured":"McCallum, C. D., Hapak, R. C., Neuenschwander, P. F., Morrissey, J. H. & Johnson, A. E. The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor. A fluorescence energy transfer study. J. Biol. Chem. 271, 28168\u201328175 (1996).","journal-title":"J. Biol. Chem."},{"key":"418_CR51","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/09537104.2017.1306042","volume":"28","author":"RM Schoeman","year":"2017","unstructured":"Schoeman, R. M., Lehmann, M. & Neeves, K. B. Flow chamber and microfluidic approaches for measuring thrombus formation in genetic bleeding disorders. Platelets 28, 463\u2013471 (2017).","journal-title":"Platelets"},{"key":"418_CR52","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1182\/blood-2014-01-551275","volume":"123","author":"P Margaritis","year":"2014","unstructured":"Margaritis, P. Does rFVIIa work solo in hemophilia? Blood 123, 1631\u20131633 (2014).","journal-title":"Blood"},{"key":"418_CR53","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3324\/haematol.2018.214239","volume":"105","author":"JP Botero","year":"2020","unstructured":"Botero, J. P. et al. Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica 105, 888\u2013894 (2020).","journal-title":"Haematologica"},{"key":"418_CR54","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/bloodadvances.2021005142","volume":"5","author":"L Buitrago","year":"2021","unstructured":"Buitrago, L., Lefkowitz, S., Bentur, O., Padovan, J. & Coller, B. Platelet binding to polymerizing fibrin is avidity driven and requires activated \u03b1IIb\u03b23 but not fibrin cross-linking. Blood Adv. 5, 3986\u20134002 (2021).","journal-title":"Blood Adv."},{"key":"418_CR55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood.V80.1.25.25","volume":"80","author":"P Wildgoose","year":"1992","unstructured":"Wildgoose, P. et al. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 80, 25\u201328 (1992).","journal-title":"Blood"},{"key":"418_CR56","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood.V81.3.734.734","volume":"81","author":"JH Morrissey","year":"1993","unstructured":"Morrissey, J. H., Macik, B. G., Neuenschwander, P. F. & Comp, P. C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81, 734\u2013744 (1993).","journal-title":"Blood"},{"key":"418_CR57","first-page":"102","volume":"26","author":"U Hedner","year":"1996","unstructured":"Hedner, U. Dosing and monitoring NovoSeven treatment. Haemostasis 26, 102\u2013108 (1996).","journal-title":"Haemostasis"},{"key":"418_CR58","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/psp4.12872","volume":"11","author":"A Faraj","year":"2022","unstructured":"Faraj, A. et al. Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: a novel hemostatic drug. CPT Pharmacometrics Syst. Pharmacol. 11, 1628\u20131637 (2022).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"418_CR59","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00277-005-1080-y","volume":"84","author":"MC Ozelo","year":"2005","unstructured":"Ozelo, M. C., Svirin, P. & Larina, L. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard\u2013Soulier syndrome. Ann. Hematol. 84, 816\u2013822 (2005).","journal-title":"Ann. Hematol."},{"key":"418_CR60","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/hae.13804","volume":"25","author":"A Tj\u00e4rnlund-Wolf","year":"2019","unstructured":"Tj\u00e4rnlund-Wolf, A. & Lassila, R. Phenotypic characterization of haemophilia B\u2014understanding the underlying biology of coagulation factor IX. Haemophilia 25, 567\u2013574 (2019).","journal-title":"Haemophilia"},{"key":"418_CR61","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.25910","volume":"95","author":"MW Blaauwgeers","year":"2020","unstructured":"Blaauwgeers, M. W. et al. Bleeding phenotype and diagnostic characterization of patients with congenital platelet defects. Am. J. Hematol. 95, 1142\u20131147 (2020).","journal-title":"Am. J. Hematol."},{"key":"418_CR62","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1002\/ajh.25667","volume":"95","author":"MW Blaauwgeers","year":"2020","unstructured":"Blaauwgeers, M. W. et al. The limitation of genetic testing in diagnosing patients suspected for congenital platelet defects. Am. J. Hematol. 95, E26\u2013E28 (2020).","journal-title":"Am. J. Hematol."},{"key":"418_CR63","doi-asserted-by":"publisher","first-page":"7785","DOI":"10.1021\/bi00420a030","volume":"27","author":"L Thim","year":"1988","unstructured":"Thim, L. et al. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 27, 7785\u20137793 (1988).","journal-title":"Biochemistry"},{"key":"418_CR64","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1021\/bi001612z","volume":"40","author":"E Persson","year":"2001","unstructured":"Persson, E., Nielsen, L. S. & Olsen, O. H. Substitution of aspartic acid for methionine-306 in factor VIIa abolishes the allosteric linkage between the active site and the binding interface with tissue factor. Biochemistry 40, 3251\u20133256 (2001).","journal-title":"Biochemistry"},{"key":"418_CR65","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/pro.5560050809","volume":"5","author":"PO Freskg\u00e5rd","year":"1996","unstructured":"Freskg\u00e5rd, P. O., Olsen, O. H. & Persson, E. Structural changes in factor VIIa induced by Ca2+ and tissue factor studied using circular dichroism spectroscopy. Protein Sci. 5, 1531\u20131540 (1996).","journal-title":"Protein Sci."},{"key":"418_CR66","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/j.1538-7836.2004.00772.x","volume":"2","author":"SA Smith","year":"2004","unstructured":"Smith, S. A. & Morrissey, J. H. Rapid and efficient incorporation of tissue factor into liposomes. J. Thromb. Haemost. 2, 1155\u20131162 (2004).","journal-title":"J. Thromb. Haemost."},{"key":"418_CR67","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1111\/jth.12427","volume":"11","author":"A Hyseni","year":"2013","unstructured":"Hyseni, A. et al. Increased mortality in systemic inflammatory response syndrome patients with high levels of coagulation factor VIIa. J. Thromb. Haemost. 11, 2111\u20132117 (2013).","journal-title":"J. Thromb. Haemost."},{"key":"418_CR68","doi-asserted-by":"publisher","DOI":"10.3791\/62952","author":"AC Illa","year":"2021","unstructured":"Illa, A. C. et al. Tail vein transection bleeding model in fully anesthetized hemophilia A mice. J. Vis. Exp. https:\/\/doi.org\/10.3791\/62952 (2021).","journal-title":"J. Vis. Exp."},{"key":"418_CR69","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/hae.12907","volume":"22","author":"PB Johansen","year":"2016","unstructured":"Johansen, P. B., Tranholm, M., Haaning, J. & Knudsen, T. Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice\u2014characterization of two novel FVIII molecules. Haemophilia 22, 625\u2013631 (2016).","journal-title":"Haemophilia"},{"key":"418_CR70","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/prot.340220412","volume":"22","author":"D Kirchhofer","year":"1995","unstructured":"Kirchhofer, D. et al. Activation of blood coagulation factor VIIa with cleaved tissue factor extracellular domain and crystallization of the active complex. Proteins 22, 419\u2013425 (1995).","journal-title":"Proteins"},{"key":"418_CR71","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"418_CR72","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"418_CR73","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"418_CR74","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"418_CR75","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1107\/S0907444912001308","volume":"68","author":"PV Afonine","year":"2012","unstructured":"Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 68, 352\u2013367 (2012).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"418_CR76","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/nsmb.3129","volume":"22","author":"G Scapin","year":"2015","unstructured":"Scapin, G. et al. Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat. Struct. Mol. Biol. 22, 953\u2013958 (2015).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"418_CR77","doi-asserted-by":"publisher","first-page":"W423","DOI":"10.1093\/nar\/gkz403","volume":"47","author":"Y Karami","year":"2019","unstructured":"Karami, Y. et al. DaReUS-Loop: a web server to model multiple loops in homology models. Nucleic Acids Res. 47, W423\u2013W428 (2019).","journal-title":"Nucleic Acids Res."},{"key":"418_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32079-w","volume":"8","author":"Y Karami","year":"2018","unstructured":"Karami, Y., Guyon, F., De Vries, S. & Tuff\u00e9ry, P. DaReUS-Loop: accurate loop modeling using fragments from remote or unrelated proteins. Sci. Rep. 8, 13673 (2018).","journal-title":"Sci. Rep."},{"key":"418_CR79","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1538-7836.2010.03826.x","volume":"8","author":"YZ Ohkubo","year":"2010","unstructured":"Ohkubo, Y. Z., Morrissey, J. H. & Tajkhorshid, E. Dynamical view of membrane binding and complex formation of human factor VIIa and tissue factor. J. Thromb. Haemost. 8, 1044\u20131053 (2010).","journal-title":"J. Thromb. Haemost."},{"key":"418_CR80","first-page":"1204","volume":"73","author":"P Bourgeat","year":"1995","unstructured":"Bourgeat, P., Jasmin, P., Migaud-Fressart, M. & Martinolli, J. L. Direct measurement of activated factor VII in plasma: development of an original assay. Thromb. Haemost. 73, 1204 (1995).","journal-title":"Thromb. Haemost."},{"key":"418_CR81","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2008)."},{"key":"418_CR82","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom, L., Pihlgren, P. & Jonsson, E. N. PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79, 241\u2013257 (2005).","journal-title":"Comput. Methods Programs Biomed."},{"key":"418_CR83","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4161\/mabs.3.1.13799","volume":"3","author":"R Deng","year":"2011","unstructured":"Deng, R. et al. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 3, 61\u201366 (2011).","journal-title":"MAbs"},{"key":"418_CR84","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1124\/dmd.116.074799","volume":"45","author":"X Chen","year":"2017","unstructured":"Chen, X., DuBois, D. C., Almon, R. R. & Jusko, W. J. Characterization and interspecies scaling of rhTNF-\u03b1 pharmacokinetics with minimal physiologically based pharmacokinetic models. Drug Metab. Dispos. 45, 798\u2013806 (2017).","journal-title":"Drug Metab. Dispos."},{"key":"418_CR85","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood.V62.4.784.784","volume":"62","author":"DS Fair","year":"1983","unstructured":"Fair, D. S. Quantitation of factor VII in the plasma of normal and warfarin-treated individuals by radioimmunoassay. Blood 62, 784\u2013791 (1983).","journal-title":"Blood"},{"key":"418_CR86","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/j.1538-7836.2006.01967.x","volume":"4","author":"R Wagenvoord","year":"2006","unstructured":"Wagenvoord, R., Hemker, P. W. & Hemker, H. C. The limits of simulation of the clotting system. J. Thromb. Haemost. 4, 1331\u20131338 (2006).","journal-title":"J. Thromb. Haemost."},{"key":"418_CR87","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1111\/j.1538-7836.2008.03188.x","volume":"6","author":"KB Neeves","year":"2008","unstructured":"Neeves, K. B. et al. Microfluidic focal thrombosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear-resistance of platelet aggregates. J. Thromb. Haemost. 6, 2193\u20132201 (2008).","journal-title":"J. Thromb. Haemost."}],"container-title":["Nature Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44161-023-00418-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-023-00418-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-023-00418-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T19:05:10Z","timestamp":1707937510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44161-023-00418-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":87,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["418"],"URL":"https:\/\/doi.org\/10.1038\/s44161-023-00418-4","relation":{},"ISSN":["2731-0590"],"issn-type":[{"value":"2731-0590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.S.G.: employee and shareholder of Hemab Therapeutics. M.Z.: no conflicts of interest. H.\u00d8.: employee and shareholder of Hemab Therapeutics. A.C.B.: employee and shareholder of Hemab Therapeutics. T.E.: employee and shareholder of Novo Nordisk. M.N.L.: employee and shareholder of Novo Nordisk. G.S.: employee and shareholder of Novo Nordisk. E.J.: employee and shareholder of Novo Nordisk. O.H.O.: received consultation fees from Hemab Therapeutics. E.H.N.O.: no conflicts of interest. I.-A.d.B.: employee of Sanquin Diagnostic Services. K.B.: employee of Sanquin Diagnostic Services. O.A.: received consultation fees from Hemab Therapeutics. C.J.R.: employee and shareholder of Hemab Therapeutics. S.E.B.: shareholder of Hemab Therapeutics. R.E.S.: the institution of R.E.S. has received speaker\u2019s fees and\/or research grants from Bayer, CSL Behring, Novartis, Novo Nordisk, Octapharma, Roche, Sobi and Takeda. B.S.: employee and shareholder of Hemab Therapeutics. R.T.U.: no conflicts of interest. J.H.F.: employee and shareholder of Hemab Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}